WallStSmart

Merck & Company Inc (MRK)vsSTRATA Skin Sciences Inc (SSKN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 214156% more annual revenue ($65.77B vs $30.70M). MRK leads profitability with a 13.6% profit margin vs -20.4%. SSKN appears more attractively valued with a PEG of 0.03. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

SSKN

Hold

45

out of 100

Grade: D

Growth: 2.7Profit: 2.5Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Intrinsic value data unavailable for SSKN.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

SSKN2 strengths · Avg: 10.0/10
PEG RatioValuation
0.0310/10

Growing faster than its price suggests

Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

SSKN4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$942,1103/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.4%3/10

Operating margin of 0.4%

Return on EquityProfitability
-158.9%2/10

ROE of -158.9% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : SSKN

The strongest argument for SSKN centers on PEG Ratio, Price/Book. PEG of 0.03 suggests the stock is reasonably priced for its growth.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : SSKN

The primary concerns for SSKN are EPS Growth, Market Cap, Operating Margin.

Key Dynamics to Monitor

MRK profiles as a value stock while SSKN is a turnaround play — different risk/reward profiles.

MRK carries more volatility with a beta of 0.20 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 45/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

STRATA Skin Sciences Inc

HEALTHCARE · MEDICAL DEVICES · USA

STRATA Skin Sciences, Inc., a medical technology company, develops, markets and markets products for the treatment of dermatological conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company is headquartered in Horsham, Pennsylvania.

Want to dig deeper into these stocks?